
Non-Sponsored Content
FDA ONCOLOGY & HAEMATOLOGY APPROVALS
Nivolumab approved for melanoma with lymph node involvement or metastatic disease after resection
By: News Feed | Last updated: 20th December 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
BMS, Bristol-Myers Squibb, FDA, nivolumab, Opdivo, PD-1
On 20 December 2017, the FDA granted regular approval to the anti-PD1 monoclonal antibody, nivolumab (Opdivo®, Bristol-Myers Squibb) for the adjuvant treatment of patients with melanoma with lymph node involvement or in patients with metastatic disease after complete resection. Nivolumab received prior FDA approval for the treatment of patients with unresectable or metastatic melanoma.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE


































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients













































































































© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!